Efficacy of antiviral therapy in combination treatment of acute respiratory viral infections in children
Objective. To assess the efficacy of Isoprinosine in children aged between 3 and 7 years with moderate acute respiratory viral infections (ARVI) during the acute period and later.
Patients and methods. We performed clinical and laboratory examination of 92 children aged between 3 and 7 years with moderate ARVI and developed a clinical and economic rationale for the use of Isoprinosine.
Results. In 30 (32.6%) out of 92 children with ARVI from both groups, the causative agent was identified. Thirteen patients (14.1%) were infected with rhinoviruses; seven patients (7.6%) had parainfluenza; 5 patients (5.4%) had bocavirus; and 5 patients (5.4%) had adenovirus. The use of Isoprinosine in the acute period of the disease promoted rapid regression of clinical symptoms, reduced the incidence of recurrent ARVI episodes, and decreased the number of complications in the followup period. The assessment of cost-effectiveness of Isoprinosine in the treatment of ARVI demonstrated feasibility of its use.
Conclusion. Antiviral and immunomodulatory effects of inosine pranobex against ARVI in children aged 3 to 7 years ensured rapid regression of clinical symptoms and reduced disease duration. The inclusion of Isoprinosine into the treatment scheme and its immunomodulatory effect decreased the incidence and the number of complications, thereby reducing the frequency of antibiotic use. Therefore, Isoprinosine in combination therapy for ARVI reduced treatment costs.
Key words: children, isoprinosine, acute respiratory infections.
For citation: Mikhaylova E.V., Levin D.Yu., Serdyukov A.Yu., Matveeva M.A., Zheleznikov P.A. Efficacy of antiviral therapy in combination treatment of acute respiratory viral infections in children. Vopr. prakt. pediatr. (Clinical Practice in Pediatrics). 2019; 14(4): 68–72. (In Russian).